{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:44:29Z","timestamp":1780397069282,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jdcr.2024.03.004","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T08:51:53Z","timestamp":1710492713000},"page":"47-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Rapid response of omalizumab-resistant chronic urticaria to acalabrutinib"],"prefix":"10.1016","volume":"47","author":[{"given":"Diamond R.","family":"Guy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Mizes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7692-1768","authenticated-orcid":false,"given":"Christopher T.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jdcr.2024.03.004_bib1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jaci.2022.10.004","article-title":"Chronic spontaneous urticaria guidelines: what is new?","volume":"150","author":"Zuberbier","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jdcr.2024.03.004_bib2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12016-021-08886-x","article-title":"Chronic urticaria: advances in understanding of the disease and clinical management","volume":"61","author":"He","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.jdcr.2024.03.004_bib3","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jdcr.2024.03.004_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaip.2016.08.010","article-title":"The comparative safety of multiple alternative agents in refractory chronic urticaria patients","volume":"5","author":"Seth","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.jdcr.2024.03.004_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3390\/jcm12010378","article-title":"IgG and IgE autoantibodies to IgE receptors in chronic spontaneous urticaria and their role in the response to omalizumab","volume":"12","author":"Maronese","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jdcr.2024.03.004_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12227","article-title":"Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of Fc\u03b5R1 expression level and omalizumab clinical response","volume":"13","author":"Gimeno","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jdcr.2024.03.004_bib7","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.12688\/f1000research.11546.1","article-title":"Chronic urticaria: a focus on pathogenesis","volume":"6","author":"Asero","year":"2017","journal-title":"F1000Res"},{"issue":"10","key":"10.1016\/j.jdcr.2024.03.004_bib8","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/jcm11102807","article-title":"Bruton's kinase inhibitors for the treatment of immunological diseases: current status and perspectives","volume":"11","author":"Robak","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdcr.2024.03.004_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.727531","article-title":"Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets\u2013beyond B lymphocytes","volume":"9","author":"Zhu","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.jdcr.2024.03.004_bib10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cancers13051103","article-title":"Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease","volume":"13","author":"von Hundelshausen","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624001000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624001000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T04:06:33Z","timestamp":1715832393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624001000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":10,"alternative-id":["S2352512624001000"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.03.004","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid response of omalizumab-resistant chronic urticaria to acalabrutinib","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}